Furthermore, we also analyzed the activation state of various signaling pathways and genes using Ingenuity Pathway Analysis (IPA) to evaluate the increased SERPINB2 expression itself and its related signaling regulators in metastatic versus non-metastatic cancers or recurrent versus nonrecurrent cases of multiple cancer types. This evidence concerns the gene SERPINB2 and cancer.